These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20802234)

  • 1. Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins.
    Kenanova VE; Olafsen T; Salazar FB; Williams LE; Knowles S; Wu AM
    Protein Eng Des Sel; 2010 Oct; 23(10):789-98. PubMed ID: 20802234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FcRn binding properties of an abnormal truncated analbuminemic albumin variant.
    Andersen JT; Daba MB; Sandlie I
    Clin Biochem; 2010 Mar; 43(4-5):367-72. PubMed ID: 20006594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics.
    Andersen JT; Cameron J; Plumridge A; Evans L; Sleep D; Sandlie I
    J Biol Chem; 2013 Aug; 288(33):24277-85. PubMed ID: 23818524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc receptor (FcRn).
    Sand KM; Bern M; Nilsen J; Dalhus B; Gunnarsen KS; Cameron J; Grevys A; Bunting K; Sandlie I; Andersen JT
    J Biol Chem; 2014 Dec; 289(50):34583-94. PubMed ID: 25344603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.
    Kenanova V; Olafsen T; Crow DM; Sundaresan G; Subbarayan M; Carter NH; Ikle DN; Yazaki PJ; Chatziioannou AF; Gambhir SS; Williams LE; Shively JE; Colcher D; Raubitschek AA; Wu AM
    Cancer Res; 2005 Jan; 65(2):622-31. PubMed ID: 15695407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody.
    Cai W; Olafsen T; Zhang X; Cao Q; Gambhir SS; Williams LE; Wu AM; Chen X
    J Nucl Med; 2007 Feb; 48(2):304-10. PubMed ID: 17268029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain.
    Andersen JT; Pehrson R; Tolmachev V; Daba MB; Abrahmsén L; Ekblad C
    J Biol Chem; 2011 Feb; 286(7):5234-41. PubMed ID: 21138843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.
    Sundaresan G; Yazaki PJ; Shively JE; Finn RD; Larson SM; Raubitschek AA; Williams LE; Chatziioannou AF; Gambhir SS; Wu AM
    J Nucl Med; 2003 Dec; 44(12):1962-9. PubMed ID: 14660722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs.
    Viuff D; Antunes F; Evans L; Cameron J; Dyrnesli H; Thue Ravn B; Stougaard M; Thiam K; Andersen B; Kjærulff S; Howard KA
    J Control Release; 2016 Feb; 223():22-30. PubMed ID: 26699424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Half-life extension of efficiently produced DARPin serum albumin fusions as a function of FcRn affinity and recycling.
    Merten H; Brandl F; Zimmermann M; Schaefer JV; Irpinio L; Sand KMK; Nilsen J; Andersen JT; Zangemeister-Wittke U; Plückthun A
    Eur J Pharm Biopharm; 2021 Oct; 167():104-113. PubMed ID: 34303832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neonatal Fc Receptor Binding Tolerance toward the Covalent Conjugation of Payloads to Cysteine 34 of Human Albumin Variants.
    Petersen SS; Kläning E; Ebbesen MF; Andersen B; Cameron J; Sørensen ES; Howard KA
    Mol Pharm; 2016 Feb; 13(2):677-82. PubMed ID: 26654692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like Peptide 1 Conjugated to Recombinant Human Serum Albumin Variants with Modified Neonatal Fc Receptor Binding Properties. Impact on Molecular Structure and Half-Life.
    Bukrinski JT; Sønderby P; Antunes F; Andersen B; Schmidt EGW; Peters GHJ; Harris P
    Biochemistry; 2017 Sep; 56(36):4860-4870. PubMed ID: 28799326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin.
    Schmidt EGW; Hvam ML; Antunes F; Cameron J; Viuff D; Andersen B; Kristensen NN; Howard KA
    J Biol Chem; 2017 Aug; 292(32):13312-13322. PubMed ID: 28637874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement.
    Larsen MT; Rawsthorne H; Schelde KK; Dagnæs-Hansen F; Cameron J; Howard KA
    J Control Release; 2018 Oct; 287():132-141. PubMed ID: 30016735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface.
    Schmidt MM; Townson SA; Andreucci AJ; King BM; Schirmer EB; Murillo AJ; Dombrowski C; Tisdale AW; Lowden PA; Masci AL; Kovalchin JT; Erbe DV; Wittrup KD; Furfine ES; Barnes TM
    Structure; 2013 Nov; 21(11):1966-78. PubMed ID: 24120761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fc engineering: serum half-life modulation through FcRn binding.
    Olafsen T
    Methods Mol Biol; 2012; 907():537-56. PubMed ID: 22907373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein.
    Seijsing J; Lindborg M; Höidén-Guthenberg I; Bönisch H; Guneriusson E; Frejd FY; Abrahmsén L; Ekblad C; Löfblom J; Uhlén M; Gräslund T
    Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17110-5. PubMed ID: 25406323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural insights into neonatal Fc receptor-based recycling mechanisms.
    Oganesyan V; Damschroder MM; Cook KE; Li Q; Gao C; Wu H; Dall'Acqua WF
    J Biol Chem; 2014 Mar; 289(11):7812-24. PubMed ID: 24469444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein.
    Yazaki PJ; Kassa T; Cheung CW; Crow DM; Sherman MA; Bading JR; Anderson AL; Colcher D; Raubitschek A
    Nucl Med Biol; 2008 Feb; 35(2):151-8. PubMed ID: 18312824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.